whitepaper Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software 29 November 2018 | By Thermo Fisher Scientfic Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
news Amgen and Immatics to collaborate on bispecific cancer immunotherapies 13 January 2017 | By Niamh Marriott (Drug Target Review) The collaboration will combine Immatics’ Xpresident target discovery and T-cell receptor (TCR) capabilities with Amgen’s validated Bispecific T-cell Engager (BiTE) technology with the aim of creating novel oncology drugs.
news Amgen sponsors the QB3@953 life sciences incubator 23 June 2016 | By Victoria White, Digital Content Producer Amgen has announced a five-year, platinum sponsorship of the QB3@953 life sciences incubator to accelerate the development of new therapies...
news Scientists discover dual role of IL-36 in inflammatory bowel disease 17 February 2016 | By Victoria White Scientists have discovered the dual role of IL-36 in both promoting intestinal inflammation and resolving or healing that inflammation in IBD...
news Amgen Foundation invests $4 million in the Amgen Biotech Experience 22 October 2015 | By Victoria White The Amgen Biotech Experience was designed to inspire the next generation of innovators and give school students the opportunity to experience real science...
news Amgen and Xencor enter cancer immunotherapy and inflammation collaboration 17 September 2015 | By Victoria White The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb bispecific technology platform...
news Amgen to highlight new data for investigational cholesterol-lowering medication evolocumab 13 November 2014 | By Amgen Thirteen presentations include new analyses of PCSK9 inhibitor at upcoming American Heart Association Scientific sessions...
news Amgen announces positive Phase 3 results for AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis 18 July 2014 | By Amgen Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...
news Amgen and AstraZeneca announce positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis 12 May 2014 | By AstraZeneca Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints...
news Amgen announces positive top-line results from Phase 3 TESLA trial of evolocumab in patients with homozygous familial hypercholesterolemia 17 March 2014 | By Amgen Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia - a rare and serious disease...
news Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer 12 March 2014 | By Amgen Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
news Amgen And MSD announce collaboration to evaluate investigational combination treatment for advanced melanoma 5 February 2014 | By Amgen Amgen and MSD announced that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec...
